[HTML][HTML] KASL clinical practice guidelines for management of chronic hepatitis B
Korean Association for the Study of the … - Clinical and …, 2019 - ncbi.nlm.nih.gov
Diseases (AASLD) also presented and continued to revise their clinical practice guidelines,
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
and the latest updates were in 2015, 2017, and 2018. However, since the medical …
Meta‐analysis: chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin
Background Emerging data suggest that statins, aspirin and metformin may protect against
hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited …
hepatocellular carcinoma (HCC) development. However, prior meta‐analyses were limited …
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
PC Tsai, HT Kuo, CH Hung, KC Tseng, HC Lai… - Journal of …, 2023 - Elsevier
Background & Aims Diabetes mellitus (DM) is known to increase the risk of hepatocellular
carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate …
carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate …
Statin use decreases the incidence of hepatocellular carcinoma: an updated meta-analysis
Statins can decrease hepatocellular carcinoma (HCC) occurrence, but the magnitude and
the predictors of these effects remain unclear. This meta-analysis provides a pooled …
the predictors of these effects remain unclear. This meta-analysis provides a pooled …
Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies
Background and Aims: Statins are the first-line medication to treating hypercholesterolemia.
Several studies have investigated the impact of statins on the risk of hepatocellular …
Several studies have investigated the impact of statins on the risk of hepatocellular …
Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes
CH Tseng - Liver International, 2018 - Wiley Online Library
Background Whether metformin may reduce hepatocellular carcinoma (HCC) risk requires
confirmation. Methods Type 2 diabetes patients newly diagnosed during 1999‐2005 and …
confirmation. Methods Type 2 diabetes patients newly diagnosed during 1999‐2005 and …
[HTML][HTML] Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases
Despite the increasing prevalence of metabolic disorders, the potential effects of metabolic
factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver …
factors on hepatocellular carcinoma (HCC) development in individuals with chronic liver …
Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study
OBJECTIVES: The protective effect of statins in cirrhosis and its decompensation in chronic
hepatitis B (CHB) patients remains unknown. METHODS: We conducted a population-based …
hepatitis B (CHB) patients remains unknown. METHODS: We conducted a population-based …
Is metformin poised for a second career as an antimicrobial?
Metformin, a widely used antihyperglycaemic, has a good safety profile, reasonably
manageable side‐effects, is inexpensive, and causes a desirable amount of weight loss. In 4 …
manageable side‐effects, is inexpensive, and causes a desirable amount of weight loss. In 4 …
A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin
We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-
COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality …
COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality …